References

¹ Rosen WG, Mohs RC, Davis KL.. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984;141:1356-1364.

²Stern RG, Mohs RC, Davidson M et al. A longitudinal study of Alzheimer's disease: measurement, rate and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390-396.

^3. Peripheral and Central Nervous System Drugs Advisory Committee Meeting, July l7, 1989. Rockville, MD: Dept of Health and Human Services. Public Health Service, Food and Drug Administration; 1989:227.

^4. Reisberg M, Ferris SH. CIBIC-plus Interview Guide. 1994.

^5. DeJong R, Osterlund OW, Roy GW. Measurement of quality-of-life changes in patients with Alzheimer disease. Clin Ther 1989;139:1136-1139.

^6.Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurol 1997;48(5 Suppl 6):S10-16.

^7. Jann MW. Rivastigmine, a new generation cholinesterase inhibitor for the treatment of Alzheimer’s disease. Pharmacotherapy 2000;20(1):1-12.

^8.Cummings JL. Cholinesterase inhibitors: A new class of psychotropic compounds. Am J Psychiatry 2000;157(1):4-15.

^8a.Nordberg A, Svensson AL. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf. 1998 Dec;19(6):465-80

^9.Knapp MJ, Knopman DS, Solomon PR et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. J Am Med Assoc 1994;271:985-991.

^10. Rogers SL.,Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998;158(9):1021-3.

^11. Rogers SL., Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50(1):136-45.

^12.Rogers SL, Freidhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. European Neuropsychopharmacology 1998; 8(1):67-75.

^13. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderate Alzheimer’s disease. Int J Geriatr Psychopharmacology 1998;1:55-65.

^15.Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomized controlled trial. BMJ 1999;318:633-640.

^15a. Harvey AL. The pharmacology of galanthamine and its analogues. Pharmacol Ther 1995;68(1):113-28.

^15b.Maelicke A. Allosteric Modulation of Nicotinic Receptors as a Treatment Strategy for Alzheimer's Disease. Dement Geriatr Cogn Disord 2000 Sep;11 Suppl S1:11-18.

^15c.Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000 Jun 27;54(12):2261-8.

^15d. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD.The Galantamine USA-10 Study Group. Neurology. 2000 Jun 27;54(12):2269-76.

^15e. Blesa R. Galantamine: therapeutic effects beyond cognition. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:28-34.

^16. Lyketsos CG, Corazzini K, Steele CD, et al. Guidelines for the use of tacrine in Alzheimer's disease: clinical application and effectiveness. Johns Hopkins Dementia Research Clinic. J Neuropsychiatry and Clinical Neurosciences 1996;8:67-73.

^17. Lovestone S,Graham N,Howad R. Guidelines on drug treatments for Alzheimer’s disease. Lancet 1997;350:232-233.

^18. Masaki KH, Losonczy KG, Izmirlian G, et al. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology. 2000 Mar 28;54(6):1265-72

^19. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997; 336(17):1216-1222.

^20. Canadian Coordinating Office of Health Technology Assessment (CCOHTA). Drug treatments for Alzheimer’s disease: I. A comparative analysis of clinical trials. May 2000.

^21.Kawas, C, Resnick, S, Morrison, A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging. Neurology 1997; 48:1517.

^22.Tang, MX, Jacobs, D, Stern, Y, et al. Effect of estrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348:429.

^23. Yaffe, K, Sawaya, G, Lieberburg, I, et al. Estrogen therapy in postmenopausal women. Effects on cognitive function and dementia. JAMA 1998; 279:688.

^24. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA. 2000 Feb 23;283(8):1007-15.

^25. Le Bars PL, Katz MM, Berman N, et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA. 1997 Oct 22-29;278(16):1327-32.

^26. Bai DL, Tang XC, He XC. Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease. Curr Med Chem. 2000 Mar;7(3):355-74.

^27. Cheng DH, Tang XC. Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Pharmacol Biochem Behav 1998 Jun;60(2):377-86.

^28. Xu SS, Gao ZX, Weng Z, et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Acta Pharmacol Sin.1995;16 (5): 391-395.

^29. Parsons CG, Danysz W, Quack G.Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data.Neuropharmacology. 1999 Jun;38(6):735-67.

^30. Namenda [package insert]. St. Louis, MO: Forest Pharmaceuticals, Inc.; 2003

^31. Reisberg B, Doody R, Stoffler A et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003 Apr 3;348(14):1333-41.

^32. Tariot PN, Farlow MR, Grossberg GT, etal. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004 Jan 21;291(3):317-24.